Literature DB >> 9771927

Hormone-induced refractoriness to mammary carcinogenesis in Wistar-Furth rats.

L Sivaraman1, L C Stephens, B M Markaverich, J A Clark, S Krnacik, O M Conneely, B W O'Malley, D Medina.   

Abstract

One of the most consistent results in the epidemiology of human breast cancer is the inverse relationship of risk and early full-term parity. The goal of this study was to investigate the molecular mechanisms through which early full-term pregnancy protects the breast from cancer development. We used Wistar-Furth (WF) rats as our experimental system and mimicked pregnancy using estrogen and progesterone (E/P). Sexually mature female rats were treated with steroid hormones for 21 days and after 28 days of gland involution, the rats were administered MNU. Rats that received a high dose of 20 microg E and 20 mg P exhibited an 82% reduction in the incidence of mammary adenocarcinomas as compared to the rats receiving only blank pellets. Decreasing doses of E/P were partially protective suggesting that complete differentiation of the gland was not required for refractoriness. We measured the RNA expression levels of several target genes involved in the regulation of mammary cell proliferation and/or differentiation including estrogen receptor (ER) and progesterone receptor (PR), cyclins D1 and D2, the cell cycle inhibitors p16, p21 and p27, and the tumor suppressor p53. At the time of MNU treatment we found no significant differences in the expression of these genes, with the possible exception of p21, indicating that hormone treatment did not result in constitutive changes in expression levels. The numbers of apoptotic cells were low and comparable in the hormone exposed and age-matched virgin gland (AMV) at the time of carcinogen challenge and remained low for 8 days after MNU treatment. The number of BrdU-labeled cells at the time of carcinogen challenge were also low in both the AMV (1.8%) and hormone exposed (0.8%) animals. In contrast, cell proliferation in the AMV (5.7%) was significantly different from both the parous involuted (1.2%) and the E/P-treated involuted (1.5%) animals 8 days after MNU treatment. We interpret these data to indicate that hormone treatment results in mammary epithelial cells that have persistent alterations in intracellular pathways governing proliferation responses to carcinogens.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9771927     DOI: 10.1093/carcin/19.9.1573

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  40 in total

Review 1.  Mammary epithelial stem cells: transplantation and self-renewal analysis.

Authors:  Gilbert H Smith; Corinne A Boulanger
Journal:  Cell Prolif       Date:  2003-10       Impact factor: 6.831

Review 2.  Hormone-induced protection against breast cancer.

Authors:  Lakshmi Sivaraman; Daniel Medina
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-01       Impact factor: 2.673

3.  17β-Estradiol alters oxidative damage and oxidative stress response protein expression in the mouse mammary gland.

Authors:  Lisi Yuan; Alicia K Dietrich; Yvonne S Ziegler; Ann M Nardulli
Journal:  Mol Cell Endocrinol       Date:  2016-02-09       Impact factor: 4.102

Review 4.  Pregnancy and stem cell behavior.

Authors:  Kay-Uwe Wagner; Gilbert H Smith
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-01       Impact factor: 2.673

5.  A noncoding RNA is a potential marker of cell fate during mammary gland development.

Authors:  Melanie R Ginger; Amy N Shore; Alejandro Contreras; Monique Rijnkels; Jonathan Miller; Maria F Gonzalez-Rimbau; Jeffrey M Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-30       Impact factor: 11.205

6.  Isoflavones - Mechanism of Action and Impact on Breast Cancer Risk.

Authors:  Johannes Stubert; Bernd Gerber
Journal:  Breast Care (Basel)       Date:  2009-02-20       Impact factor: 2.860

7.  Pathways contributing to development of spontaneous mammary tumors in BALB/c-Trp53+/- mice.

Authors:  Haoheng Yan; Anneke C Blackburn; S Christine McLary; Luwei Tao; Amy L Roberts; Elizabeth A Xavier; Ellen S Dickinson; Jae Hong Seo; Richard B Arenas; Christopher N Otis; Qing J Cao; Rebecca G Lawlor; Barbara A Osborne; Frances S Kittrell; Daniel Medina; D Joseph Jerry
Journal:  Am J Pathol       Date:  2010-01-28       Impact factor: 4.307

8.  Hormonal prevention of breast cancer: mimicking the protective effect of pregnancy.

Authors:  R C Guzman; J Yang; L Rajkumar; G Thordarson; X Chen; S Nandi
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

9.  p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis.

Authors:  L Sivaraman; O M Conneely; D Medina; B W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

10.  Inter-Individual Variation in Response to Estrogen in Human Breast Explants.

Authors:  Karen A Dunphy; Amye L Black; Amy L Roberts; Aman Sharma; Zida Li; Sneha Suresh; Eva P Browne; Kathleen F Arcaro; Jennifer Ser-Dolansky; Carol Bigelow; Melissa A Troester; Sallie S Schneider; Grace Makari-Judson; Giovanna M Crisi; D Joseph Jerry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2020-03-09       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.